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role of misoprostol in postpartum hemorrhage
prevention
Ndola Prata1*, Suzanne Bell2 and Md Abdul Quaiyum3Abstract
Background: Bangladesh is one of the few countries that may actually achieve the fifth Millennium Development
Goal (MDG) in time, despite skilled birth attendance remaining low. The purpose of this paper is to examine the
potential role misoprostol can play in the decline of maternal deaths attributed to postpartum hemorrhage (PPH) in
Bangladesh.
Methods: Using data from a misoprostol and blood loss measurement tool feasibility study in Bangladesh,
observed cause specific maternal mortality ratios (MMRs) were estimated and contrasted with expected ratios using
estimates from the Bangladesh Maternal Mortality Survey (BMMS) data. Using Crystal Ball 7 we employ Monte Carlo
simulation techniques to estimate maternal deaths in four scenarios, each with different levels of misoprostol
coverage. These scenarios include project level misoprostol coverage (69%), no (0%), low (40%), and high (80%)
misoprostol coverage. Data on receipt of clean delivery kit, use of misoprostol, experience of PPH, and cause of
death were used in model assumptions.
Results: Using project level misoprostol coverage (69%), the mean number of PPH deaths expected was 40
(standard deviation = 8.01) per 100,000 live births. Assuming no misoprostol coverage (0%), the mean number of
PPH deaths expected was 51 (standard deviation = 9.30) per 100,000 live births. For low misoprostol coverage (40%),
the mean number of PPH deaths expected was 45 (standard deviation = 8.26) per 100,000 live births, and for high
misoprostol coverage (80%), the mean number of PPH deaths expected was 38 (standard deviation = 7.04) per
100,000 live births.
Conclusion: This theoretical exercise hypothesizes that prophylactic use of misoprostol at home births may
contribute to a reduction in the risk of death due to PPH, in addition to reducing the incidence of PPH. If findings
from this modeling exercise are accurate and uterotonics can prevent maternal death, misoprostol could be the
tool countries need to further reduce maternal mortality at home births.
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Maternal mortality remains a major challenge in many set-
tings with more than 99% of global maternal deaths still
occurring in low-resource countries [1,2]. The lifetime risk
of a woman dying in pregnancy or within 42 days of its
termination is approximately 1 in 150 in developing coun-
tries and 1 in 38,000 in developed countries [3]. The fifth
Millennium Development Goal (MDG) strove to address
the high levels of maternal mortality throughout the world
by calling for a reduction in the maternal mortality ratio
(MMR) by three-quarters from 1990 to 2015 [4]. The
international maternal health community’s strategy to
achieve this goal has primarily focused on increasing ac-
cess to skilled birth attendants (SBAs) and emergency ob-
stetric care (EmOC), but women delivering outside of
health facilities have largely not benefited from these ef-
forts [5].
Nearly half of all births worldwide (46%) still occur
outside of an institutional setting, attended by a trad-
itional birth attendant (TBA), a relative, or no one [6,7].
Part of the reason that more deliveries are not attended
by an SBA is the fact that many settings with high
MMRs have low ratios of SBAs to women and progress
in this regard has remained slow [8]. TBAs that attend
these births typically do not have appropriate technolo-
gies to manage or treat complications, which explains
many studies’ findings that TBA trainings are not effect-
ive at improving maternal survival [9]. Despite these
discouraging findings, research has shown that appro-
ximately 80% of maternal deaths are due to avoidable
causes, among which hemorrhage is a leading cause
[10,11]. Hemorrhage is estimated to be responsible for
approximately 35% of maternal deaths in developing
countries, although this varies widely across regions/
countries [12,13]. Postpartum hemorrhage (PPH), blood
loss of 500 ml or more, is responsible for the majority of
the maternal deaths due to hemorrhage [14]. PPH poses
a significant public health challenge in low-resource set-
tings because of its low predictability [15] and the speed
at which it kills; without intervention, 88% of women
who die of postpartum hemorrhage die within four
hours of delivery [16].
Misoprostol is a generic, low cost, heat-stable uterotonic
that can be orally administered in tablet form for the pre-
vention of PPH. Operations research has demonstrated
the safety, feasibility, and acceptability of low-level pro-
viders, or women themselves, administering misoprostol
for PPH prevention during home deliveries in low-
resource settings [17-23]. In addition, two randomized
controlled trials (RCTs) evaluated the use of 600 micro-
grams of misoprostol compared to a placebo to prevent
PPH in home births [24,25]. In rural India, Derman et al.
demonstrated a statistically significant 47% reduction in
the relative risk of PPH (RR = 0.53, 95% CI 0.39-0.74) [24].Mobeen et al. illustrated that TBAs using misoprostol at
home births in Pakistan could reduce the relative risk of
PPH by 24% (RR = 0.76, 95% CI 0.59-0.97) [25]. Based
on a review of existing evidence, the World Health
Organization (WHO) added misoprostol to the Essential
Medicines List for the prevention of PPH in 2011 and
now supports non-skilled birth attendant administration
of misoprostol at home deliveries [26,27]. Incorporating
misoprostol at home deliveries has the potential to avert
PPH attributable maternal deaths at the community level
where most women in low-resource settings give birth.
Bangladesh is one of the few countries that may actu-
ally achieve the fifth MDG in time, despite SBA attend-
ance remaining low. Recent estimates put the MMR at
194 maternal deaths per 100,000 live births, which is im-
pressive given that approximately 71% of births take
place at home, of which only 4.3% are attended by a
skilled provider [28]. Estimates show that 31% of ma-
ternal mortality is attributable to hemorrhage in this
context, highlighting the need for community-based in-
terventions like misoprostol to reduce preventable ma-
ternal deaths [29].
The purpose of this paper is to examine the potential
role misoprostol can play in the decline of maternal
deaths attributed to PPH at home births in Bangladesh.
This study uses empirical data from a PPH prevention
program and findings from previously published RCTs
to model the number of PPH deaths that would result
from four different scenarios of misoprostol coverage.
Scenario 1 represents the project level coverage of 69%;
scenario 2, 3, and 4 hypothetically represent no coverage
(0%), low coverage (40%), and high coverage (80%),
respectively.
Study context
Operations research to evaluate the feasibility and ac-
ceptability of scaling-up community-based use of miso-
prostol and a postpartum blood loss measurement tool
was conducted in six districts of the Rangpur Division in
Bangladesh from May 2009 through September 2010.
The study was a collaboration between a local non-
governmental organization, Rangpur Dinajpur Rural Ser-
vices (RDRS), the International Centre for Diarrheal
Disease Research, Bangladesh (icddr,b) in Dhaka, the
University of California, Berkeley Bixby Center for Popu-
lation, Health, and Sustainability, and Venture Strategies
Innovations. A total of 696 RDRS field staff, including
585 RDRS TBAs, received a two day training on mi-
soprostol (function, dosage, timing of administration,
side effects and their management, etc.) and use of the
blood measurement tool, which was designed to absorb
500 mL of blood after delivery of the baby and be a vis-
ual cue to indicate the onset of PPH when the mat was
full. The training also covered identifying high-risk
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dures, stages of labor, newborn resuscitation, maternal
infection, and use of the clean delivery kits. The miso-
prostol and blood measurement tool were added to
RDRS’s existing clean delivery kit (CDK) at no extra
charge and were distributed to clients registered with
RDRS during antenatal care (ANC), or at the time of de-
livery by a TBA.
A total of 118,500 women enrolled in the study, of
which 77,337 delivered during the project monitoring
period. Of those, 67,611 (87%) delivered at home. Verbal
autopsies for all maternal deaths that occurred in the
study areas during the project period were conducted.
Ethical permission for the study was granted by the Uni-
versity of California, Berkeley (CPHS # 2010-01-619).
Additional information on the study can be found in the
final report [30]. Study results on training TBAs to use
misoprostol and the blood loss measurement tool in
home births in Bangladesh have been published else-
where [31].
Methods
Cause specific maternal mortality data used in this analysis
came from verbal autopsies conducted in the project de-
scribed above. Verbal autopsy interviews were conducted
with persons who were most familiar with the specifics
surrounding the maternal death using an adapted version
of the tool available from the WHO [for more recent
version, see: [32]]. Each verbal autopsy questionnaire was
independently reviewed by two physicians in order to de-
termine an immediate cause of maternal death using theFigure 1 Flow chart of categorization of women who delivered at ho
death due to PPH.International Classification of Disease (ICD) 10 [33]. Final
cause of death categories used include the main obstetric
or direct causes of maternal death and a group of indirect
causes. Cause of death categories used in this study differ
from those in the study’s final report because researchers
combined cause of death categories to better reflect the
Bangladesh Maternal Mortality Survey (BMMS) catego-
rization [29,30]. Observed cause specific maternal mortal-
ity ratios are estimated and contrasted with expected
ratios using estimates from the BMMS data [29].
For model building, we use project data on CDK
coverage and misoprostol utilization from ANC cards
and cause of death data from the verbal autopsies to
categorize women (Figure 1). Coverage data includes the
percentage of women who received the CDK, and miso-
prostol utilization is the percent of those who received
the CDK who used the misoprostol (Table 1). To esti-
mate the effectiveness of misoprostol in reducing PPH
we use data from two RCTs where misoprostol was
shown to reduce PPH by 24% to 47% when administered
at home deliveries by lay providers (Mobeen, RR = 0.76,
95% CI 0.59-0.97; Derman, RR = 0.53, 95% CI 0.39-0.74)
[24,25]. In these RCTs, 17% and 6% of women experi-
enced PPH if they took misoprostol, compared to 22%
and 12% if they did not [24,25]. Reviews of RCTs com-
paring misoprostol to a placebo, although not necessarily
at the community level or involving lay healthcare workers,
have found risk ratios within this range, but not all findings
have been significant [34-36]. The intervention did incorp-
orate an absorbent delivery mat to visually estimate blood
loss, but the delivery mat was not always utilized (68% ofme by receipt of CDK, use of misoprostol, experience of PPH, and
Table 1 Assumptions in Monte Carlo modeling scenarios
%
Minimum Likeliest Maximum Distribution Source of assumption
Assumptions used in all scenarios
% used misoprostol had PPH 6 12 17 Triangle RCTs
% used misoprostol died of PPH 0.2 0.3 0.4 Triangle Project data
% did not use misoprostol had PPH 12 17 22 Triangle RCTs
% did not use misodied of PPH 0.2 0.3 0.4 Triangle Project data
Scenario specific assumptions
Scenario 1: Project data
% received CDKs 49 69 89 Triangle Project data
% received CDK used miso 80 94 100 Triangle Project data
% did not use miso 0 6 20 Triangle Project data
Scenario 2: No misoprostol coverage
% received CDKs 0 0 0 Uniform Set level
% received CDK used miso 0 0 0 Uniform Set level
% did not use miso 100 100 100 Uniform Set level
Scenario 3: Low misoprostol coverage
% received CDKs 20 40 60 Triangle Set level
% received CDK used miso 80 94 100 Triangle Project data
% did not use miso 0 6 20 Triangle Project data
Scenario 4: High misoprostol coverage
% received CDKs 60 80 100 Triangle Set level
% received CDK used miso 80 94 100 Triangle Project data
% did not use miso 0 6 20 Triangle Project data
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whether the mat was filled. Women self-reported whether
they thought they experienced PPH at a postnatal appoint-
ment. If they used the mat, PPH was reported based on
visual estimation resulting from the mat being soiled.
However, in the case of a maternal death, someone in-
volved in the delivery reported whether he/she thought the
woman experienced PPH. We believe that blood loss esti-
mation to establish PPH was more accurately measured in
the RCTs, thus we used the prevalence of PPH among
those who did and did not take misoprostol from previous
RCTs in our modeling assumptions. Mortality data accord-
ing to whether or not the woman had used misoprostol
and died of PPH was taken from the verbal autopsy reports
from the project data (Table 1).
We employed Monte Carlo modeling techniques using
Crystal Ball 7, a stochastic modeling supplement for
Excel [37]. Monte Carlo simulations are computational
algorithms that utilize repeated random sampling by
running simulations many times as a way of estimating
probabilities. Assumption parameters are set for all vari-
ables included in the simulation, which determine the
likely range of possibilities. Data on receipt of CDK, use
of misoprostol, experience of PPH, and cause of deathwere used to estimate parameters for the model. Most
assumptions were assigned a triangle distribution, where
the likeliest value in the distribution was drawn from the
empirical evidence in our study or the literature, with an
associated minimum and maximum value (Table 1).
Our modeling began with a hypothetical population of
100,000 singleton live births from Bangladeshi women,
all of whom delivered at home. As seen in Figure 1, this
population was divided into those who received a CDK
and those who did not, and then those who used miso-
prostol and those who did not. We divided these groups
into those who experienced PPH and those who did not.
Lastly, we divided those who experienced PPH into
those who died from PPH and those who did not. Thus
our main outcome in the model was the total number of
PPH related deaths. The percentages in Table 1 were
used in the Monte Carlo simulation to calculate the
likely probability that a woman would be in each of
these categories along the “decision tree” presented in
Figure 1, and ultimately, the range of probabilities that
she would die of postpartum hemorrhage.
We influenced the coverage of misoprostol to create a
series of scenarios, each of which was run 50,000 times.
In scenario 1, the coverage assumption was set using the
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prostol coverage at 0%; in scenario 3 we set the miso-
prostol coverage low at 40%; and in scenario 4 we set
the misoprostol coverage high at 80%. We also calcu-
lated overall MMRs and the associated number of ma-
ternal deaths country-wide for each scenario, keeping
all other cause specific maternal mortality ratios the
same using BMMS data. We wanted to generate overall
MMR estimates that incorporated scenario specific PPH
MMRs and were generalizable to the entire country but
there was evidence of significant differences between
project and BMMS cause specific MMRs, thus we used
BMMS cause specific MMRs. We used the most recent
Bangladesh estimate for the total number of annual
births to calculate the total number of maternal deaths
in each of the four scenarios [38]. Lastly, we conducted
a perturbation of estimates for each scenario to investi-
gate the robustness of the estimates to changes in under-
lying assumptions.
Results
Overall, 117 women died during the study period, 54
(46%) of whom died of PPH or bleeding related causes
(Table 2). Among women who delivered at home during
the study period (67,611), 69% received the CDK; among
those, 94% used the misoprostol. Among this sub-
population of home deliveries that was used to inform
the Monte Carlo simulation assumptions, 34 women
died of PPH; 17 who took misoprostol, 16 who did not,
and 1 whose misoprostol usage is unknown (Table 2).Table 2 Attributed cause of death, timing of death, use of mi
verbal autopsy data from operations research in Bangladesh
based use of misoprostol and a postpartum hemorrhage bloo
Cause of death
Number
of
maternal
deaths
%
distribution
by cause
Timing of death
Before
delivery
During
delivery
Direct obstetric
causes 110 94.0 24 17
PPH and bleeding
related
54 46.2 4 7
Antepartum
hemorrhage (APH)
5 4.3 1 3
Eclampsia 27 23.1 11 3
Obstructed labor 2 1.7 0 2
Ruptured uterus 2 1.7 1 0
Other direct causes 20 17.1 7 2
Indirect causes 7 6.0 3 0
Total 117 100.0 27 17
1Two women are missing information on timing of death, one who died of PPH and
2Options were: home, upazilla health complex, upazilla health and family welfare ce
center, in between hospital and home, other, and not applicable. “Facility” is all cat
3Skilled attendant is doctor or nurse/midwife.
4Unskilled includes RDRS TBA, untrained TBA, relative, village doctor, self, and otherTable 2 provides additional information on the cause of
death, timing of death, place of delivery, and attendant
at delivery among all maternal deaths in the study.
Based on the number of maternal deaths, we calcu-
lated overall and cause specific MMRs for the project
and compared these to the expected MMRs based on
the BMMS data (Table 3). The project estimated PPH
specific MMR was 71.9 deaths per 100,000 live births
whereas the BMMS PPH [combined with antepartum
hemorrhage (APH)] cause specific MMR was 60.2 deaths
per 100,000 live births. This difference was not statisti-
cally significant, though some of the cause specific
MMRs were statistically significantly different. These in-
clude obstructed labor, other direct causes, and indirect
causes. These differences are likely due to differences in
the categorization of maternal deaths. We were unable
to compare cause specific MMRs for APH and ruptured
uterus because these cause of death categories were not
used in the BMMS report.
Table 4 contains results from the four scenarios mod-
eled using Monte Carlo simulation. We used project
level data along with results from RCTs investigating the
efficacy of misoprostol for PPH prevention at home
births to inform the assumptions for the model. Using
project level misoprostol coverage (69%), the mean
number of PPH deaths expected was 40 (standard devi-
ation = 8.01) per 100,000 live births. Assuming no miso-
prostol coverage (0%), the mean number of PPH deaths
expected was 51 (standard deviation = 9.30) per 100,000
live births. For low misoprostol coverage (40%), thesoprostol, place of delivery, and provider at delivery from
assessing the feasibility and acceptability of community-
d loss measurement tool (N=117)
1
Took
misoprostol
Place of
delivery2 Attendant at delivery
After
delivery Home Facility
Skilled
attendant3
Unskilled
attendant4
67 27 44 34 37 67
42 17 34 15 19 31
1 1 0 2 1 4
13 3 4 12 11 14
0 0 0 0 0 2
1 1 1 0 0 2
10 5 5 5 6 14
4 0 3 1 1 6
71 27 47 35 38 73
onewho died of other direct causes.
nter, private hospital/clinic, government hospital, maternal and child welfare
egories except home, between hospital and home, other, and not applicable.
.
Table 3 Observed and expected cause specific maternal mortality ratios
Cause of death
Number
of
maternal
deaths
Deaths/100,000 live births
p-value
Project estimated MMR Expected MMR (based on BMMS)1 Difference
PPH and bleeding related2 54 71.9 60.2 11.73 0.309
Antepartum hemorrhage (APH) 5 6.7 N/A N/A N/A
Eclampsia 27 36.0 38.6 -2.63 0.763
Obstructed labor 2 2.7 12.5 -9.84 0.012
Ruptured uterus 2 2.7 N/A N/A N/A
Other direct causes 20 26.6 11.4 15.2 0.014
Indirect causes 7 9.3 68.2 -58.9 <0.001
Total 117 156 194 -38 0.042
1Also had category “undetermined”, MMR=2.3.
2Hemorrhage (PPH and APH) for BMMS data.
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deviation = 8.26) per 100,000 live births, and for high mi-
soprostol coverage (80%), the mean number of PPH
deaths expected was 38 (standard deviation = 7.04) per
100,000 live births.
Using BMMS data for all cause specific MMRs other
than PPH (which total 134 per 100,000 live births) and
holding these ratios constant regardless of the level of
misoprostol coverage, we calculated overall MMRs for
each scenario and applied these MMRs to Bangladesh’s
most recent estimate for the total number of annual
births [38]. This allowed us to calculate the total esti-
mated number of maternal deaths for the country
(Table 4). Using the project level scenario, 5,286 mater-
nal deaths would occur at the national level. For the no
misoprostol, low misoprostol, and high misoprostol sce-
narios, 5,620, 5,438, and 5,225 maternal deaths would
occur, respectively, at the national level. This indicates
that, given the assumptions of the scenarios, an esti-
mated 395 PPH related maternal deaths could be avertedTable 4 Mean number of PPH specific maternal deaths and as
population of 100,000 Bangladeshi women who delivered liv
Ball
Scenario Misoprostolcoverage
Mean number of PPH
deaths/PPH specific
MMR
Range of
number of PPH
deaths
Project
level
69% 40 15-76
No
misoprostol
0% 51 25-85
Low
misoprostol
40% 45 20-83
High
misoprostol
80% 38 17-70
1Calculated from BMMS MMRs (overall MMR, 194; overall MMR excluding PPH speci
the same level as BMMS.
2Based on recent estimate of 3,038,000 annual births [38].by increasing the misoprostol coverage at home births
from 0% to 80% nationwide.
The results from the sensitivity analyses reveal varying
levels of contribution of each component to the variance
in the number of PPH maternal deaths based on the as-
sumptions in each scenario (Figure 2). In scenario 1 (pro-
ject data, 69% coverage), “using misoprostol and having
PPH” and “not using misoprostol” were the components
that contributed the most to the variance in the number
of PPH deaths, 29% and 28%, respectively. In scenario 2
(no misoprostol, 0% coverage), “not using misoprostol and
dying of PPH” and “not using misoprostol and having
PPH” were the only factors, the former of which contrib-
uted the greatest to the variance in the number of PPH
maternal deaths; “not using misoprostol and dying of
PPH” contributed slightly more than half of the variance
in the total number of PPH deaths. In scenario 3 (low mi-
soprostol, 40% coverage), “not using misoprostol and
dying of PPH” had the highest level of contribution to
the variance in the outcome (28%), but “not usingsociated PPH specific and overall MMRs in a hypothetical
e births at home across 4 scenarios modeled using Crystal
SD of the
sample
mean
Expected number of all
other maternal deaths1
Overall
MMR1
Estimated number
of maternal
deaths2
8.01 134 174 5,286
9.30 134 185 5,620
8.26 134 179 5,438
7.04 134 172 5,225
fic MMR, 134) with the assumption that all other causes of death happened at
Figure 2 Results from sensitivity analyses.
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encing PPH” (22%) were similarly high. In scenario 4 (high
misoprostol, 80% coverage), “using misoprostol and ex-
periencing PPH” was the component that contributed
most to the variance in the number of PPH maternal
deaths at 51%.
Discussion
Results theorize the potential contribution misoprostol
utilization at home births can have on the number of
PPH attributable deaths and how this might affect the
overall number of maternal deaths in Bangladesh if this
intervention were brought to scale. This is the first mod-
eling exercise that uses maternal mortality data from a
single intervention to investigate the potential impact of
prophylactic misoprostol use on PPH mortality. The
data for this exercise come primarily from the largest
misoprostol/PPH prevention intervention conducted in
a low-resource setting, providing ample amounts of data
from which we could formulate assumptions for the
simulations.
Our findings estimate the range of PPH specific
MMRs and total number of maternal deaths that could
result from four different scenarios with varying levels ofmisoprostol coverage. If Bangladesh had no misoprostol
coverage at home births, the estimated PPH specific
MMR would be 51 deaths per 100,000 live births. This is
in contrast to the estimated PPH specific MMR with
high (80%) misoprostol coverage, which would result in
38 deaths per 100,000 live births. If brought to scale,
based on the assumptions of the simulations, this inter-
vention has the potential to greatly reduce the total
number of maternal deaths. These findings highlight
how a PPH prevention intervention at home births
could have a substantial impact on maternal mortality,
especially in countries such as Bangladesh where a large
number of births take place at home.
Despite the vast amount of data and number of
women involved in the study, this project and associated
analyses had several limitations. Most importantly, alter-
native explanations could also be used to explain the dif-
ference in mortality among those who did and did not
take misoprostol. Perhaps the difference is simply due to
an ecological association, whereby women who live
closer to a facility are more likely to access ANC ser-
vices, receive and use the misoprostol, and then more
likely to access and receive life-saving care in the event
of complications. Previous research found that increased
Prata et al. BMC Pregnancy and Childbirth 2014, 14:78 Page 8 of 10
http://www.biomedcentral.com/1471-2393/14/78distance to a facility was associated with increased risk
of maternal mortality, but this was among women who
delivered with a skilled provider; this association did not
hold among those who delivered without a skilled pro-
vider [39]. All the women in the data used to calculate
the assumptions for this modeling exercise delivered at
home without a skilled provider, they were all enrolled
in private sector ANC through RDRS (who recruited
women in these rural areas door-to-door), and they
could all request an RDRS TBA to be present at their
delivery, who brought CDKs in the event that the
woman had not already received one. Thus we feel it is
unlikely that women who did not receive/use misopros-
tol were systematically further from a health facility than
those who did. However, we acknowledge it is possible
that underlying factors inherent in the woman who used
the misoprostol and the mat (e.g. motivation, knowledge,
etc.) also made her more likely to be transferred earlier
and to receive appropriate life-saving care since the
women were not randomized to use the interventions or
not. The strongest evidence against this explanation is
that the probability of death among those who experi-
enced PPH was equal among those who did and did not
take misoprostol (0.3%), thus mortality was reduced via
a decrease in the incidence of PPH, not a decrease in the
risk of death once one experienced PPH.
On the whole, the PPH MMRs from the simulations
are lower than that of the project data and the BMMS
data. We hypothesize that it could be due to the fact that
some women who were at high risk, who experienced
obstetric complications early on during labor, or who
had heavy bleeding immediately after labor could have
been transferred to a facility and not been categorized as
having delivered at home; per training instructions, im-
mediate transfer was promoted in cases of heavy bleed-
ing. This would likely result in an increase in the PPH
MMR among facility deliveries and a decrease in the
PPH MMR among home births than would otherwise
have been expected.
The cause of death categories in the BMMS report do
not align with our categories. For instance, the BMMS re-
port combines PPH and APH deaths into “hemorrhage”
whereas we wanted to isolate PPH attributable deaths,
thus we kept PPH as a separate category. This difference,
among others, resulted in the cause specific MMRs not
being entirely comparable. Although not ideal, we include
them nonetheless for exploration, knowing also that the
BMMS MMR is for the entire country, accounting for
rural and urban deliveries and home and facility deliveries;
the project data contains 87% home deliveries, which is
above the national average of 71%, and the entire popula-
tion is rural [28]. One would expect the project estimate
to be higher given the great percentage of home deliveries
and rural residents in comparison to the country as awhole, but our overall MMR was in fact lower. This could
be due to the fact that all women were enrolled with a
local NGO that provided ANC and delivery services. Des-
pite these differences, using the BMMS MMR as the ex-
pected MMR and contrasting that with scenario specific
PPH MMRs allows us to make broad yet tenuous general-
izations about the total number of maternal deaths ex-
pected at a national level. Because the scenario specific
PPH MMRs were much lower than the study or the
BMMS PPH MMRs, our findings are likely conservative
estimates of the total number of PPH deaths that could be
averted at the national level in Bangladesh.
The use of verbal autopsy to determine cause of death
is a limitation. Because of the number of women in-
volved in the study and the fact that nearly all deliveries
were conducted at home without a skilled provider, re-
searchers had to rely on interviews with someone (often
a close relative) involved in the delivery of each woman
who died in the study. Given the nature of the interven-
tion, which included an IEC campaign about the dangers
of PPH specifically, there was a heightened awareness
among women and families of the risk of PPH, and a
blood collection mat was used to assess bleeding. This
could have contributed to increases in the reporting of
bleeding when other symptoms or signs were ignored
and not reported, resulting in differential misclassifica-
tion of cause of death, with more deaths being classified
by those interviewed for the verbal autopsy as a death
due to excessive bleeding. This would help to explain
why the study’s PPH specific MMR was much higher
than the BMMS estimate.
The assumption that the rate of PPH mortality is con-
stant across the population is another limitation. The
more marginalized women who do not attend ANC and
who do not receive a CDK likely have a higher PPH
mortality rate than those who do. We were unable to es-
timate and incorporate these potential differences in our
modeling, thus the findings do not accurately capture
the fact that increasing coverage may not be linearly as-
sociated with reductions in PPH mortality.
Additionally, incomplete data on one PPH maternal
death resulted in the exclusion of the case because we
could not categorize the death according to misoprostol
use. The potential difference that would result from the
correct categorization of this woman would not be sub-
stantial, thus we do not feel this significantly biased our
results.
Despite these limitations, the results of this modeling
exercise hypothesize the potential differences in overall
maternal deaths that could result from varying levels of
misoprostol coverage throughout the country. Compared
to no misoprostol coverage, findings indicate that achiev-
ing 80% coverage (with 94% utilization among that 80%)
might be associated with a reduction in the overall MMR
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this is equivalent to a 7% reduction in overall maternal
mortality. The 7% reduction represents about a quarter
(23%) of the 31% of total maternal mortality that is attrib-
utable to PPH in Bangladesh. The remaining 77% of PPH
maternal mortality could require a stronger uterotonic,
more uterotonics, or other interventions in order to pre-
vent mortality among these cases. Little is known about
the causes of PPH that result in mortality, thus it could
be that of the 31% of maternal deaths due to PPH in
Bangladesh, only 23% of it can be prevented by misopros-
tol and the remainder would require other interventions;
this is less than previously thought given the assumption
that most PPH is due to uterine atony, which would be re-
sponsive to uterotonics.
The overall reduction in maternal mortality from this
study is actually lower than that observed in other mod-
eling exercises [40-42]. If true, this could mean a de-
crease in the cost-effectiveness of this approach [40,41].
Use of misoprostol for PPH treatment is a more cost-
effective intervention [41], but it would require getting
more women to deliver in facilities and encouraging
early transfer among home births in order to treat PPH
cases, which are difficult to predict [15]. Nonetheless,
the hypothetical scenarios in this modeling exercise
present the possibility that many lives could be saved in
Bangladesh, and other countries, by increasing coverage
of misoprostol availability among women delivering at
home; a potential 7% reduction in MMR is not an insig-
nificant number of lives saved. Additional empirical evi-
dence is needed to confirm the results of this modeling
exercise and the incidence of PPH mortality among
women who do and do not take misoprostol.
Conclusion
This theoretical exercise hypothesizes that prophylactic
use of misoprostol at home births may contribute to a re-
duction in the risk of death due to PPH, in addition to re-
ducing the incidence of PPH, if uterotonics can in fact
prevent maternal death. Even after the WHO’s decision to
support misoprostol use for PPH prevention at home
births, there have been continued opponents of misopros-
tol use for this purpose, claiming insufficient evidence
[43]. Other researchers pooled existing study data to deter-
mine the potential impact of misoprostol on PPH mortal-
ity and found that its use neither increased nor decreased
mortality or severe morbidity [44]. The findings from our
modeling exercise support the case for misoprostol use at
home births in low-resource settings and hypothesize the
potential reductions in maternal death due to PPH that
can be achieved with various levels of misoprostol cover-
age, incorporating empirical data from a large field trial. If
findings from this modeling exercise correspond to the
possible effect of misoprostol use on PPH mortality,misoprostol could be the tool that countries need in order
to further reduce maternal mortality at home births.
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